


SUPPLEMENTARY DATA

**Supplementary Figure 1.** Flowchart of Wounds Included in Cox Analyses



SUPPLEMENTARY DATA

**Supplementary Table 1.** Baseline Characteristics of All Wounds by Wound Outcome

Characteristics	All Wounds		
	Not Healed N = 134	Healed N = 450	All N= 584
Time to Wound Outcome, days	103.0 (146)	80.0 (113)	85.0 (126)
Female/Male, %	37.3/62.7	38.2/61.8	38.0/62.0
Age, years	58.5 (15.5)	57.1 (15.8)	57.2 (15.8)
Race*, %			
White/Caucasian	49.6	32.7	36.5
Black	45.1	64.9	60.4
Other	5.3	2.4	3.1
BMI †, kg/m <sup>2</sup>	29.0 (12.1)	31.1 (10.7)	30.7 (11.1)
Type 1/ Type 2 Diabetes Mellitus,	8.2/91.8	4.7/95.3	5.5/94.5
Diabetes duration, years	15.2 (12.9)	15.4 (13.3)	15.3 (13.3)
Baseline A1C, %	7.7 (3.1)	7.9 (3.5)	7.8 (3.4)
Nadir A1C, %	6.9 (2.2)	7 (1.9)	7 (2.0)
Mean A1C, %	7.4 (2.8)	7.6 (2.6)	7.6 (2.7)
Nadir A1C Change from Baseline	-0.3 (1.2)	-0.4 (1.5)	-0.4 (1.4)
Mean A1C Change from Baseline	-0.13 (0.6)	-0.07 (1.2)	-0.1 (1)
Target A1C, %			
<7.0%	32.8	36.0	35.3
7.0% - 7.5%	67.2	64.0	64.7
Observed/Expected A1C (IOR) per	1 (0.2)	1(0.2)	1 (0.2)
Number (%) with >1 prospective	120 (89.6)	390 (86.7)	510 (87.3)
Antihyperglycemic medications, %			
Metformin	30.6	37.3	35.8
DPP-4 inhibitors	7.5	4.9	5.5
GLP-1 agonists	2.2	1.6	1.7
Thiazolidenediones	0.8	0.2	0.3
SGLT-2 inhibitors	0	0	-
Sulfonylureas	13.4	14.9	14.6
Sulfonylurea types, %			
Glyburide	0	9.8	7.7
Glimepiride	47.1	27.9	32.1
Glipizide	52.9	62.3	60.3
Insulin, %	76.1	62.2	65.4
Total insulin dose (units/kg/day),			
0.00	22.4	37.0	33.6

SUPPLEMENTARY DATA

Characteristics	All Wounds		
	Not Healed N = 134	Healed N = 450	All N= 584
0.07-0.53	26.9	35.2	33.3
0.53-3.28	50.8	27.8	33.1
Comorbidities, %			
Coronary artery disease	26.9	22.2	23.3
Prior myocardial infarction	11.9	12.9	12.7
Peripheral vascular disease	50.8	40.0	42.5
Prior amputation	26.9	37.6	35.1
Hypertension	82.1	84.0	83.6
Loss of protective sensation	94.8	94.4	94.5
Retinopathy	29.9	20.1	22.6
Dialysis	18.7	8.9	11.1
Prior kidney transplant	12.7	7.1	8.4
eGFR <sub>‡</sub> categories, %			
G1 - 2	34.4	28.4	29.8
G3	24.0	35.8	33.0
G4	16.8	20.2	19.4
G5	24.8	15.6	17.8
Current smoker, %	66.4	55.6	58.1
WIFI§ stage, %			
1	17.9	35.8	31.7
2	14.9	18.4	17.6
3	29.9	28.2	28.6
4	37.3	17.6	22.1
Uninfected wounds at baseline			
No antibiotics, N (%)	49/61 (80.3)	198/233 (85.0)	247/294 (84.0)
Antibiotic Use, N (%)	12/61 (19.7)	35/233 (15.0)	47/294 (16.0)
Infected wounds at baseline			
No antibiotics, N (%)	0/73 (0)	2/217 (0.9)	2/290 (0.7)
Antibiotic use, N (%)	73/73 (100)	215/217 (99.1)	288/290 (99.3)
Antibiotic use, %	63.4	55.6	57.4
Wound intervention, %			
Wound care	43.3	40.0	40.8
Surgery	56.7	60.0	59.2

Data are mean ± standard deviation or median (interquartile range, IQR). *P*-values were calculated using Students *t* test for continuous variables with normal distribution and Wilcoxon rank sum test for non-normally distributed variables. *P*-values not reported for “All Wounds” because of lack of independence of characteristics for multiple wounds per participant. Bolded= *P*<0.05. Fisher’s exact test or  $\chi^2$

## SUPPLEMENTARY DATA

tests were used for categorical variables. \*Race missing 1 observation in Not Healed category. †BMI missing 1 observation in Healed category. ‡eGFR laboratory result missing for 9 observations in Not Healed category and 45 observations in Healed category. §WIFI = Wound, Ischemia, and Foot Infection classification of the Society for Vascular Surgery.

SUPPLEMENTARY DATA

**Supplementary Table 2.** Baseline Characteristics of Wounds by Long-Term ( $\geq 90$  days) Wound Outcome Stratified by Baseline A1C Status (One Random Wound Per Participant)

Characteristics	One Wound Per Participant (Random)							
	Baseline A1C <7.5%				Baseline A1C $\geq 7.5\%$			
	Not Healed	Healed	All	*P-value	Not Healed	Healed	All	*P-Value
Wounds, N	14	40	54		23	58	81	
Time to Wound Outcome, days	154 (78)	185 (141)	174 (132)	0.40	119 (84)	170 (154)	164 (133)	<b>0.02</b>
Female/Male, %	35.7/64.3	40.0/60.0	38.9/61.1	0.77	60.9/39.1	44.8/55.2	49.4/50.6	0.19
Age, years	64.3 $\pm$ 13.8	60.5 $\pm$ 11.2	61.5 $\pm$ 11.9	0.32	60.0 $\pm$ 10.5	54.7 $\pm$ 11.3	56.2 $\pm$ 11.3	0.06
Race <sup>†</sup> , %				0.71				0.46
White/Caucasian	50.0	40.0	42.6		30.4	20.7	23.5	
Black	50.0	57.5	55.6		69.6	75.9	74.1	
Other	0.0	2.5	1.9		0.0	3.5	2.5	
BMI <sup>‡</sup> , kg/m <sup>2</sup>	34.2 (12.2)	31.2 (13.7)	32.7 (13.4)	0.65	31.7 (14.1)	32.1 (9.9)	32.0 (10.4)	0.85
Type 1/ Type 2 Diabetes Mellitus, %	0/100	12.5/87.5	9.3/90.7	0.17	8.7/91.3	5.2/94.8	6.2/93.8	0.55
Diabetes duration, years	16.8 $\pm$ 8.2	18.9 $\pm$ 11.3	18.4 $\pm$ 10.6	0.53	18.1 (28.3)	18.1 (11.0)	18.1(12.6)	0.62
Baseline A1C,%	6.3 $\pm$ 0.7	6.3 $\pm$ 0.7	6.3 $\pm$ 0.7	0.91	10.1 (4.1)	9.8 (2.4)	9.8 (2.9)	0.70
Nadir A1C, %	6.2 (1.1)	6.2 (1.0)	6.2 (1.0)	0.80	7.4 (3.2)	7.6 (2.4)	7.6 (2.8)	0.64
Mean A1C, %	6.4 (1.9)	6.5 (1.2)	6.5 (1.1)	0.39	8.9 (2.4)	8.3 (2.1)	8.3 (2.7)	0.80
Nadir A1C Change from Baseline	-0.1 (0.6)	0.0 (0.7)	0.0 (0.5)	0.35	-2.6 (2.3)	-1.5 (1.1)	-1.9 (2.7)	0.07
Mean A1C Change from Baseline	0.0 (0.5)	0.1 (1.6)	0.0 (0.6)	0.08	-1.5 (2.8)	-0.7 (2.7)	-0.9 (2.6)	0.14
Target A1C, %				0.78				0.12
<7.0%	14.3	17.5	16.7		26.1	44.8	39.5	
7.0% - 7.5%	85.7	82.5	83.3		73.9	55.2	60.5	
Observed/Expected A1C (IQR) per 90-days	0.9 (0.9)	1.1 (0.9)	1.0 (0.9)	0.21	1.2 (0.8)	1.3 (0.6)	1.3 (0.7)	0.82
Number (%) with $\geq 1$	14	36 (90.0)	50 (92.6)	0.22	21 (91.3)	54 (93.1)	75 (92.6)	0.78

SUPPLEMENTARY DATA

prospective A1C	(100.0)							
Antihyperglycemic medications, %								
Metformin	21.4	32.5	29.6	0.44	21.7	32.8	29.6	0.33
DPP-4 inhibitors	0.0	7.5	5.6	0.56	8.7	5.2	6.2	0.62
GLP-1 agonists	0.0	0.0	0.0	-	0.0	0.0	0.0	-
Thiazolidenediones	0.0	2.5	1.9	1.00	0.0	0.0	0.0	-
SGLT-2 inhibitors	0.0	0.0	0.0	-	0.0	0.0	0.0	-
Sulfonylureas	7.1	10.0	9.3	1.00	21.7	15.5	17.3	0.53
Sulfonylurea types, n (%)				0.20				0.46
Glyburide	0/1 (0.0)	0/4 (0.0)	0/5 (0.0)		0/5 (0.0)	2/8 (25.0)	2/13 (15.4)	
Glimepiride	1/1/ (100.0)	0/4 (0.0)	1/5 (20.0)		3/5 (60.0)	2/8 (25.5)	5/13 (38.4)	
Glipizide	0/1 (0.0)	4/4 (100.0)	4/5 (80.0)		2/5 (40.)	4/8 (50.0)	6/13(46.2)	
Insulin, %	57.1	45.0	48.2	0.43	87.0	82.8	84.0	0.64
Total insulin dose† (units/kg/day), %				0.62				<b>0.02</b>
Tertile 1	42.9	56.4	52.8		21.7	37.9	33.3	
Tertile 2	21.4	12.8	15.1		21.7	37.9	33.3	
Tertile 3	35.7	30.8	32.1		56.5	24.1	33.3	
Comorbidities, %								
Coronary artery disease	34.8	20.7	24.7	0.19	34.8	20.7	24.7	0.19
Prior myocardial infarction	17.4	13.8	14.8	0.68	17.4	13.8	14.8	0.68
Peripheral vascular disease	52.2	39.7	43.2	0.31	52.2	39.7	43.2	0.31
Prior amputation	26.1	25.9	25.9	0.98	26.1	25.9	25.9	0.98
Hypertension	95.7	86.2	88.9	0.22	95.7	86.2	88.9	0.22
Loss of protective sensation (LOPS)	100.0	91.4	93.8	0.15	100.0	91.4	93.8	0.15
Retinopathy	34.8	24.1	27.2	0.33	34.8	24.1	27.2	0.33
Dialysis	8.7	6.9	7.41	0.78	8,7	6.9	7.4	0.78
Prior kidney transplant	8.7	3.5	4.9	0.33	8.7	3.5	4.9	0.33

SUPPLEMENTARY DATA

eGFR   categories, %				0.56				0.56
G1 - 2	22.7	32.1	29.5		22.7	32.1	29.5	
G3	22.7	28.6	26.9		22.7	28.6	26.9	
G4	36.4	21.4	25.6		36.4	21.4	25.6	
G5	18.2	17.9	18.0		18.2	17.9	18.0	
Current smoker, %	65.2	50.0	54.3	0.22	65.2	50.0	54.3	0.22
Wifi†   stage, %				<b>0.02</b>				<b>0.02</b>
1	4.4	27.6	21.0		4.3	27.6	21.0	
2	8.7	12.1	11.1		8.7	12.1	11.1	
3	26.1	32.8	30.9		26.1	32.7	30.9	
4	60.9	27.6	37.0		60.9	27.6	37.0	
Uninfected wounds at baseline (n=31), %				0.90				0.90
No antibiotics	66.7 (4/6)	64.0 (16/25)	64.5 (20/31)		66.7 (4/6)	64.0 (16/25)	64.5 (20/31)	
Antibiotic Use	33.3 (2/6)	36.0 (9/25)	35.5 (11/31)		33.3 (2/6)	36.0 (9/25)	35.5 (11/31)	
Infected wounds at baseline (n=50), %				-				-
No antibiotics	0.0	0.0	0.0		0.0	0.0	0.0	
Antibiotic use	100.0 (17/17)	100.0 (33/33)	100.0 (50/50)		100.0 (17/17)	100.0 (33/33)	100.0 (50/50)	
Antibiotic use, %	82.6	72.4	75.3	0.34	782.6	72.4	75.3	0.34
Wound intervention, %				0.84				0.84
Wound care	30.4	32.8	32.1		30.4	32.8	32.1	
Surgery	69.6	67.2	67.9		69.6	67.2	67.9	

N= Number of Wounds; data are mean ± standard deviation or median (interquartile range, IQR). \*P-values were calculated using Student's *t* test for continuous variables with normal distribution and Wilcoxon rank sum test for non-normally distributed variables. Fisher's exact test or  $\chi^2$  tests were used for categorical variables. Bolded=  $P < 0.05$ . †Insulin doses (units/kg/day) for A1C <7.5%: tertile 1 (0.0), tertile 2 (0.12-0.27), tertile 3 (0.28-2.31); For A1C  $\geq$ 7.5%, tertile 1 (0.0 – 0.30), tertile 2 (0.31-0.62), tertile 3 (0.62 – 2.54).

SUPPLEMENTARY DATA

**Supplementary Table 3.** Baseline Characteristics of Wounds by Long-Term ( $\geq 90$  days) Wound Outcome Stratified by Baseline A1C Status (All Wounds)

Characteristics	One Wound Per Participant (All Wounds)					
	Baseline A1C <7.5%			Baseline A1C $\geq 7.5\%$		
	Not Healed	Healed	All	Not Healed	Healed	All
Wounds, N	36	99	135	42	111	153
Time to Wound Outcome, days	187.5 (182)	170 (166)	179 (178)	173 (112)	163 (141)	168 (145)
Female/Male, %	25.0/75.0	36.4/63.6	33.3/66.7	47.6/52.4	43.2/56.8	44.4/55.6
Age, years	59.9 $\pm$ 16.3	60.0 $\pm$ 11.7	60.0 $\pm$ 13	58.7 (8.8)	55.0 (16.2)	57.2 (13.6)
Race†, %						
White/Caucasian	41.7	41.4	41.5	52.4	24.3	32.0
Black	52.8	56.6	55.6	47.6	73.0	66.0
Other	5.6	2.0	3.0	0.0	2.7	2.0
BMI‡, kg/m <sup>2</sup>	28.8 (11.9)	31.7 (14.0)	31.1 (13.9)	33.0 (13.9)	31.7 (9.5)	31.9 (10.5)
Type 1/ Type 2 Diabetes Mellitus, %	2.8/97.2	9.1/90.9	7.4/92.6	14.3/85.7	2.7/97.3	5.9/94.1
Diabetes duration, years	13.8 (10.1)	17.8 (19.7)	16.8 (16.3)	18.4 (27.8)	17.4 (12.6)	17.9 (12.7)
Baseline A1C, %	6.5 (0.9)	6.2 (1.1)	6.3 (1.0)	9.5 (2.5)	10 (4.1)	9.7 (3.3)
Nadir A1C, %	6.1 (1.0)	6.2 (1.0)	6.2 (0.9)	7.4 (2.9)	7.3 (1.9)	7.4 (2.2)
Mean A1C, %	6.4 (0.7)	6.4 (1.2)	6.4 (1.0)	8.9 (3.1)	8.3 (2.6)	8.6 (2.7)
Nadir A1C Change from Baseline	-0.2 (0.7)	0 (0.3)	0 (0.5)	-1.9 (3.1)	-1.5 (2.7)	-1.6 (2.8)
Mean A1C Change from Baseline	0 (0.5)	0.05 (0.9)	0 (0.8)	-0.5 (3.3)	-0.7 (2.5)	-0.7 (2.7)
Target A1C, %						
<7.0%	22.2	15.2	17.0	21.4	45.1	38.6
7.0% - 7.5%	77.8	84.8	83.0	78.6	54.9	61.4
Observed/Expected A1C (IQR) per 90-days	0.9 (0.8)	1.2 (0.9)	1.0 (1.0)	1.2 (0.7)	1.4 (0.8)	1.4 (0.8)
Number (%) with $\geq 1$ prospective A1C Antihyperglycemic medications, %	36 (100.0)	93 (93.9)	129 (95.6)	39 (92.9)	104 (93.7)	143 (93.5)



SUPPLEMENTARY DATA

Metformin	27.8	30.3	29.6	40.5	32.3	34.6
DPP-4 inhibitors	5.6	6.1	5.9	16.7	4.5	7.8
GLP-1 agonists	0.0	0.0	0.0	0.0	0.9	0.7
Thiazolidenediones	0.0	1.0	0.74	0.0	0.0	0.0
SGLT-2 inhibitors	0.0	0.0	0.0	0.0	0.0	0.0
Sulfonylureas	5.6	11.1	9.6	23.8	15.3	17.7
Sulfonylurea types, n (%)						
Glyburide	0.0	0.0	0.0	0.0	31.3	19.2
Glimepiride	100.0	27.3	38.5	40.0	25.0	30.8
Glipizide	0.0	72.7	61.5	60.0	43.7	50.0
Insulin, %	75.0	39.4	48.9	76.2	76.6	76.5
Total insulin dose*(units/kg/day), %						
Tertile 1	25.0	61.2	51.5	26.2	36.9	34.0
Tertile 2	30.6	10.2	15.7	28.6	34.2	32.7
Tertile 3	44.4	28.6	32.8	45.2	28.8	33.3
Comorbidities, %						
Coronary artery disease	30.6	36.4	34.8	31.0	17.1	20.9
Prior myocardial infarction	19.4	22.2	21.5	14.3	12.6	13.1
Peripheral vascular disease	61.1	58.6	59.3	54.8	43.2	46.4
Prior amputation	36.1	51.5	47.4	23.8	27.9	26.8
Hypertension	72.2	90.9	85.9	97.6	86.5	89.5
Loss of protective sensation (LOPS)	94.4	99.0	97.8	93.7	100.0	95.4
Retinopathy	30.6	22.2	24.2	35.7	20.7	24.8
Dialysis	30.6	15.2	19.3	11.9	4.5	6.5
Prior kidney transplant	11.1	10.1	10.4	9.5	2.7	4.6
eGFR   categories, %						
G1 - 2	25.0	22.8	23.4	26.8	25.2	25.7
G3	25.0	25.0	25.0	24.4	40.2	35.8
G4	12.5	32.6	27.4	29.3	21.5	23.7
G5	37.5	19.6	24.2	19.5	13.1	14.9
Current smoker, %	80.6	54.6	61.5	59.5	50.5	52.9

SUPPLEMENTARY DATA

Wound stage, %						
1	16.7	33.3	28.9	2.4	26.1	19.6
2	19.4	10.1	12.6	4.8	11.7	9.8
3	38.9	24.2	28.2	33.3	33.3	33.3
4	25.0	32.3	30.4	59.5	28.8	37.3
Uninfected wounds at baseline (n=54), %						
No antibiotics	88.2 (15/17)	84.2 (48/57)	85.1 (63/74)	80.0 (8/10)	70.5 (31/44)	72.2 (39/54)
Antibiotic Use	11.8 (2/17)	15.8 (9/57)	14.8 (11/74)	20.0 (2/10)	29.5 (13/44)	27.8 (15/54)
Infected wounds at baseline (n=99), %						
No antibiotics	0.0	0.0	0.0	0.0	0.0	0.0
Antibiotic use	100.0 (19/19)	100.0 (42/42)	100.0 (61/61)	100.0 (32/32)	100.0 (67/67)	100.0 (99/99)
Antibiotic use, %	58.3	51.5	53.3	81.0	72.1	74.5
Wound intervention, %						
Wound care	38.9	24.2	28.2	33.3	27.9	29.4
Surgery	61.1	75.8	71.8	66.7	72.1	70.6

N= Number of Wounds; data are mean ± standard deviation or median (interquartile range, IQR). *P*-values not reported for “All Wounds” because of lack of independence of characteristics for multiple wounds per participant. \*Insulin doses (units/kg/day) for A1C <7.5%: tertile 1 (0.0), tertile 2 (0.11-0.24), tertile 3 (0.25-3.30); For A1C ≥7.5%, tertile 1 (0.0 – 0.25), tertile 2 (0.26-0.56), tertile 3 (0.57 – 3.28).